Article

Suresh Ramalingam on Toxicities Associated With Immunotherapy in Different Disease Types

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Suresh S. Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, comments on the difference in toxicities associated with immunotherapy.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Related Content